



## EuroSIDA Newsletter

April 2023

### Dear EuroSIDA Study Investigators,

The EuroSIDA Coordinating Centre wishes you a Happy Spring! As always, we thank you for your continued excellent work and important contributions to the EuroSIDA study. Your efforts are extremely valued and meaningful to our high level of scientific research. Below follows an update from the EuroSIDA study.

### Study Updates

#### Dataset 50 (DS50)

The DS50 data collection closed on 1<sup>st</sup> January 2023. Approximately 7,250 (out of 9,663) completed follow-up forms were collected in REDCap, and follow-up data on additional 3,900 participants were submitted via the REST submission system. In total, we have received follow-up data on approximately 11,150 out of 14,000 participants under follow-up.

Thank you for striving your best to submit the data and meet the deadlines.

This year's dataset (DS51) will open in autumn 2023. More information will follow in the next newsletter.

### Clinical Reporting Form Updates

#### Covid-19

The Covid-19 form was introduced for participants who had been admitted to the hospital for treatment of COVID-19. Since our last update, we have received 44 new

forms (total number of forms 155). For each form completed, 50 euros will be reimbursed.

## Cabotegravir

Data on injectable long-acting cabotegravir and/or long-acting rilpivirine treatment are now collected annually in two separate REDCap forms. Since our last update, we have received 57 forms (a total of 64 forms). We encourage you to fill out the next-injection forms for each injection. Reimbursement is based on a full year of follow-up, and we are interested in collecting as much data as possible.

## MISTRAL

The MISTRAL study is progressing well. We are pleased to announce that there are now 17 sites open and 188 participants (from Belgium, Croatia, the Czech Republic, Denmark, Germany, Luxembourg, Poland, and the UK) enrolled in the study. 134 of the 188 participants are new MISTRAL participants and 54 of those are existing EuroSIDA participants. The aim is to enroll 1000 participants this year with at least 2 years of follow-up in 2024-2025.

So far, 8 virtual training sessions have been held and two more training sessions are planned. If you would like to participate in a training session, you can send an e-mail to the MISTRAL Secretariat office at [mistral.rigshospitalet@regionh.dk](mailto:mistral.rigshospitalet@regionh.dk).

For more information on the MISTRAL study [click here](#).

## EuroSIDA Steering Committee Election 2023

We would like to use this opportunity to announce that it is time to elect the EuroSIDA Steering Committee (SC) for 2023-2028. Three representatives will be elected for each of the 5 regions in EuroSIDA (Northern, Western, East Central, Eastern and Southern Europe, including Argentina and Israel).

Candidates from any EuroSIDA center may run and any investigator may self-nominate or nominate another candidate. More than one candidate from each country is permitted to run for the SC. However, only one candidate can be elected per country to maintain geographical representation.

All investigators are welcome to run by expressing their interest and participation in a short motivation [letter](#) to the coordinating centre: [eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk)

This could also be a great opportunity for you to gain knowledge and build network connections among EuroSIDA sites. All nominations for the SC will be accepted until **15<sup>th</sup> May 2023**. The electronic ballots will be available in REDCap from **1<sup>st</sup> June until 1<sup>st</sup> July 2023**. For more details click [here](#).

# Reminders

## Data Processing Agreement (DPA)

We are in the process of collecting DPA from all the sites that supply plasma samples for the EuroSIDA study. If your site has received a DPA template, we kindly request you fill out the necessary information and return the document. Please let us know at the coordinating centre if you have any questions or concerns regarding the agreement.

## Staff changes

Remember to inform the EuroSIDA Coordinating Centre if there are any changes of principle investigators or other collaborating partners. This will allow the communication to be directed to the right contact person. It will also allow the EuroSIDA Coordinating Centre to maintain the study group and correct the co-authorship award. Furthermore, if a staff member no longer works at your centre or new staff members join your team, we will remove or assign REDCap access accordingly.

# Reimbursement

The 2023 reimbursement process will start in May 2023. Due to a restructuring of our database and the reimbursement process, it is possible that some sites will receive payment after summer. We apologise for any inconvenience caused. More information will follow on this matter.

# Publications and presentations

## EuroSIDA reaches 334 Publications!

The EuroSIDA study group has published 10 publications since our last newsletter. We would like to express our gratitude to the EuroSIDA colleagues and the global community of people living with HIV.

## Published in 2023

1. **Hepatitis delta infection among persons living with HIV in Europe.** EuroSIDA and SHCS. Liver Int. 2023.
2. **External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.** Swiss HIV Cohort Study, ATHENA Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. JHepatol. 2023:S0168-8278(23)00011-9.

3. **Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimes: A prospective RESPOND cohort study.** RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Clin Infect Dis.2023:ciad219.

EuroSIDA presentations at the Conference on Retroviruses and Opportunistic Infections (CROI 2023) were held in February 2023 and presentations at IWHOD were held in March 2023. Click [here](#) for an overview of the presentations.

## RESPOND Update

RESPOND completed its 6<sup>th</sup> data collection on 1<sup>st</sup> January 2023. 19 cohorts are currently involved in RESPOND with almost 40,000 individuals under active follow-up. EuroSIDA remains the largest contributor of participants in RESPOND.

RESPOND presentations at CROI and IWHOD 2023 can be found [here](#).

## EuroSIDA Staff Update

**Francesca Roper** has joined the Cohort Team as project coordinator. Francesca will be working mainly with the MISTRAL study but will also support some Public Health work. She holds an MSc in Global Health from the University of Copenhagen.

Unfortunately, we said goodbye to our IT specialist, **Dennis Karsten Kristensen** in the Cohort Team after working for us for 20 years. It was a pleasure working with him. We wish him well and thank him for his great contributions to CHIP and, the EuroSIDA study over the past many years.

The EuroSIDA team would like to say a huge thank you to **Professor Amanda Mocroft** who will be retiring at the end of May. Amanda has been involved in EuroSIDA since the very beginning contributing to 300+ publications during its 25+ years. Amanda has been an integral part of the study helping to shape the research agenda, ensuring its longevity and relevancy in an ever-changing research field, whilst always ensuring the highest quality statistical methods are applied. Additionally, she has been a valuable mentor to the numerous PhD students who have worked on the study over the last 25 years. Happy Retirement – it is definitely well deserved.



### **Why are you receiving this email?**

You are receiving this email because you are affiliated with the EuroSIDA study. By providing your contact details to the EuroSIDA Coordinating Centre, you are included in the mailing list for the EuroSIDA study.

### **Contact**

Please always feel free to contact the EuroSIDA coordinating centre at

**[eurosidea.rigshospitalet@regionh.dk](mailto:eurosidea.rigshospitalet@regionh.dk)**.

No question is too small or too big, we are happy to assist in all matters!

### **EuroSIDA Coordinating Centre.**

Rigshospitalet

CHIP, Section 2100

Blegdamsvej 9

DK-2100 Copenhagen Ø,

Denmark

Web: [www.regionh.dk](http://www.regionh.dk) [www.chip.dk](http://www.chip.dk)